introduction
Gastric cancer (GC) is the third-leading cause of global cancerrelated mortality, accounting for 841 000 deaths in 2013 [1] . Epidemiologic and clinical studies indicate the existence of significant differences in both GC incidence and overall survival rates of GC patients between Asian and Western countries [2, 3] . Age-standardized incidence rates for GC are also higher in Eastern Europe compared with Central and Western Europe [4] . These geographical patterns may be caused by differences in population-specific genetic risk factors and infectious agents such as Helicobacter pylori (H. pylori), which are contributing factors to GC development [4] [5] [6] . The diagnosis of early GC is challenging, as clinical symptoms often appear late during GC development, thereby narrowing options for surgical treatment [7] . Given the global poor survival rates of GC patients particularly in the metastatic setting, there is thus an urgent need to identify new treatments.
GCs can be classified histologically using different classification systems; two of the most popular being the Lauren classification and the WHO classification. Under the Lauren classification, GCs are characterized into two subtypes (intestinal or diffuse) while the WHO system classifies GC into four subtypes (papillary, tubular, mucinous and poorly cohesive). Presently, however, while current histopathologic systems can sometimes influence endoscopic or surgical choices, they remain insufficient to guide precise treatments for individual patients [8] . Alternative classification systems are thus required. Fortunately, recent advancements in genomic technology and high-throughput analysis have now allowed GCs to be studied at high resolution and at the molecular level. Such molecular profiling data have greatly facilitated identification of candidate driver alterations in GC such as gene mutations, chromosomal alterations, transcriptional changes and epigenetic derangements (Figure 1) . Importantly, achieving an understanding of potential driver alterations involved in GC pathogenesis can also lead to the identification of clinically important biomarkers and potential treatment targets. This is exemplified by the TOGA study where trastuzumab (an anti-Her2 antibody) combined with chemotherapy improved overall survival in Her2/ neu-positive GC patients [9, 10] . Recently, a landmark study carried out by The Cancer Genome Atlas (TCGA) research network reported the comprehensive identification of genetic alterations associated with GC, combining data from different platforms such as array-based somatic copy number analysis, wholeexome and genome sequencing, messenger RNA-sequencing, microRNA sequencing and reverse-phase protein array profiling. On the basis of an integrative analysis of this molecular information, the TCGA team proposed a classification system where GC is divided into four subtypes: EBV-positive, microsatellite-unstable, genomically stable and chromosomal instability (CIN) [11] . Such studies are based on the hypothesis that that tumor classifications based on molecular data may prove more clinically impactful compared with more traditional histopathologic classifications, in terms of treatment predictions and predicting patient prognosis [12] . molecular classification of GC gene mutations in GC Next-generation sequencing (NGS) enables the high-throughput and systematic analysis of genetic alterations in the genome, and has been used to identify novel gene mutations in GC. To date, mutations in genes related to genome integrity [13] [14] [15] , chromatin remodeling [16] [17] [18] and cell adhesion/cytoskeleton/cell motility [16, [19] [20] [21] [22] have been reported. In terms of canonical oncogenic pathways, genes involved in Wnt and receptor tyrosine kinase (RTK) signaling have also been identified to be mutated in GC. Molecularly classifying GCs based on gene mutations may benefit patients by facilitating the development of targeted therapies inhibiting pathways regulated by these genes.
Genome instability is a key cellular process whereby cells acquire mutations at an increased rate, allowing the accumulation of mutations ultimately leading to tumorigenesis. Genome instability can be caused by mutations in 'caretaker' genes that act in DNA damage detection and repair. For instance, TP53 [13, 14] and BRCA2 [15] are two key driver genes that are frequently mutated in GC. TP53 is a tumor suppressor gene encoding the p53 transcription factor that regulates growth arrest genes. Mutations in p53 abrogate the detection of DNA damage by cells, thereby resulting in aberrant cell growth [23] . Likewise, BRCA2 is involved in the repair of DNA double-strand breaks. Besides genome instability, chromatin remodeling is also emerging as an important cellular pathway in cancer development. Alterations in the chromatin structure of a cell may impact DNA accessibility to transcriptional regulators, which profoundly influence gene expression. ARID1A encodes a subunit of the SWI-SNF chromatin remodeling complex, and has been identified as a frequently mutated chromatin remodeler gene in GC. SWI-SNF is involved in the remodeling of nucleosome in an ATP-dependent manner to either activate or repress gene transcription [24] . ARID1A has been proposed to function as a tumor suppressor and suppresses cell cycle genes such as CCNE1 and E2F1 [16, 17] . Consistent with its tumor suppressor function, ARID1A mutations in GC are distributed throughout the coding region and are typically inactivating, comprising truncating mutations, and insertions/deletions resulting in reading frame alterations [16, 17] . Besides ARID1A, other SWI-SNF complex members (ARID1B, PBRM1 and SMARCC1) have also been found to be mutated in GC. Additionally, other chromatin remodeling complexes such as the MLL complex (MLL2 and MLL3), ISW1 complex (SMARCA1) and NuRD complex (CHD3, CHD4 and MBD2) and genes encoding histone-modifying proteins (SIRT1 and SETD2) are also found to be mutated in GC [16, 18] . Figure 1 . Genetic and epigenetic modification of gastric cancer (GC). The genetic alteration that contributes to GC involves gene mutations, differential gene expression as well as somatic copy number alterations (SCNAs). The epigenetic modifications involve DNA as well as histone methylation. The subtypes highlighted in red are reported in the The Cancer Genome Atlas (TCGA) study [11] .
Cell adhesion, cytoskeleton and cell motility-related genes (e.g. FAT4, CDH1, CTNNA1 and RHOA) are also mutated in GC. Such genes function to regulate intercellular and cellextracellular matrix interactions, and disruptions in the function of these genes may play a pivotal role in GC development and progression. For instance, FAT4 is a tumor suppressor belonging to the cadherin family and FAT4 mutations have been shown to compromise cell attachment [16] . Diffuse-type GCs have also been recently shown to be frequently associated with mutations in cell adhesion, cytoskeleton and cell motility-related genes including CDH1, CTNNA1 and RHOA [19, 20] . The identification of the latter mutations may suggest alternative therapeutic opportunities, as there are presently no effective drugs for diffuse-subtype GC. CDH1 encodes E-cadherin that is involved in cell-cell junctions, whereas CTNNA1 encodes α-E-catenin that mediates adhesion to cytoskeletons [19] . RHOA belongs to the Rho family which functions in the regulation of actin cytoskeleton and mutations in this gene have been shown to confer greater resistance to anoikis after substrate detachment. Tyr42, Arg5 and Gly17 residues are RhoA mutation hotspots found in GC [11, 20, 21] . Additionally, ROCK1 and ROCK2, two effectors of Rho GTPases which also belong to the Rho family, have also been found to be mutated [22] .
Pathway analysis based on NGS mutation data has also identified aberrant signaling pathways in GC. Dysregulated Wnt signaling can be caused by genetic changes in various components of this pathway such as activating mutations in CTNNB1 and inactivating mutations in APC and RNF43. CTNNB1 encodes β-catenin and its mutation inhibits the degradation of intranuclear β-catenin, resulting in continuous activation of the Wnt pathway. APC and RNF43 are negative regulators of the Wnt pathway and they negatively regulate β-catenin and Frizzled receptor, respectively. In GC, APC and RNF43 are associated with truncating or inactivating mutations that are predicted to abolish their function thus stimulating the Wnt pathway [13, 25, 26] . The involvement of Wnt signaling in GC makes it a promising pathway for drug targeting. For instance, ETC-159 is a Wnt pathway inhibitor developed in Singapore and has recently advanced into phase I clinical trials. This drug can potentially be used to treat several cancers reliant on the Wnt pathway [27] . Similarly, aberrant activation of RTK-associated pathways can also lead to GC development. For instance, the ERBB3 RTK and the NRG1/ERBB4 ligand/RTK pair have been reported to be mutated in GC at frequencies of >10% [15, 28] . Another pathway that acts downstream of RTK signaling is the PI3K pathway, involved in cell growth, proliferation and survival [29, 30] . The PIK protein is a core component of the pathway and comprises the catalytic PIK3CA and regulatory PIK3R1 unit [31] . PIK3CA is frequently found to be mutated in EBV-positive and MSI subtype GC, and these PIK3CA mutations may increase kinase activity and oncogenic potential. Other PIK pathway genes such as AKT1, AKT2 and AKT3 have been reported to be mutated albeit at a lower frequency than PIK3CA [13, 14] . Additionally, mutations in the PTEN inhibitory factor have also been observed [13, 14] . Molecules targeting the PIK pathway are promising candidates for GC treatment. Success in clinical trials has already been seen in patients with PIK3CA (E545K, E542K or H1047R) or PTEN mutations who have received PI3K/AKT/mTOR inhibitors. This involves patients with diverse advanced cancers such as colorectal cancer, ovarian cancer, melanoma cancer, breast cancer and GC. Patients with PIK3CA or PTEN mutations have been reported to have a higher remission rate when compared with patients without the mutations [32] . An understanding of the involvement of the RTK/PIK pathways and their downstream signaling in GC development is thereby essential to facilitate effective drug treatments for patients.
chromosomal instability
Somatic copy number alterations (SCNAs) comprise structural variations in DNA that arise due to alterations in DNA copy number, likely caused by genome instability. SCNAs can involve focal genomic regions or broad chromosomal regions of DNA. SCNAs are very common in cancers and can be detected via cytogenetic studies, array-based profiling or NGS approaches [33] [34] [35] [36] . In GC, specific SCNAs are associated with histologic type [37] . Copy number gains at 8q, 17q and 20q are associated with intestinal GC, whereas gains at 12q and 13q are associated with diffuse GC [37, 38] . SCNAs may influence patient survival as well as other clinicopathologic parameters. For instance, both 1q gain and 18q loss have both been associated with poor prognosis [39] . Focal SCNAs have also led to the identification of cancer-causing genes in GC [20, 40, 41] , such as amplifications of genes involved in RTK/RAS/MAPK signaling, cell cycle regulation and transcription factors [11, 40, 41] . Deng et al. reported that GCs exhibit frequent amplifications in genes of the RTK/ RAS/MAPK signaling pathway, and used ERBB2, EGFR, MET, FGFR2 and KRAS amplifications to classify GCs into five subgroups, allowing for personalized treatment of each subgroup by different drugs. For instance, ERBB2, EGFR, MET and FGFR2 can be targeted by drugs trastuzumab, nimotuzumab, onartuzumab and AZD4547, respectively. Essentially 37% of the GC population can potentially be treated with drugs targeting the RTK/RAS/MAPK signaling pathway [41] [42] [43] . In spite of the availability of these drugs to their targets, it is crucial to acknowledge that not all drugs have been successful. For instance, lapatinib that was tested in the TYTAN [44] and LOGiC [45] trials did not show survival advantages in HER2-amplified GC patients. In the study carried out by the TCGA network, they reported amplifications at 9p24.1 at locus containing the gene JAK2 kinase in the EBV subgroup [11] . In addition, two other genes such as PD-L1 and PD-L2 (immune checkpoint inhibitor) have also been reported to be frequently amplified in the EBVpositive subgroup [11] .
Cell cycle-related genes such as CCND1, CCNE1 and CDK6 are commonly amplified in GC. Interestingly, through integrative analysis of the GC amplification landscape, co-amplifications of cell cycle-related genes with other oncogenes have been reported. For instance, CCNE1 is frequently co-amplified with HER2 [41] and GC patients with CCNE1/HER2 co-amplification typically developed resistance to lapatinib, a small molecular HER2 inhibitor [46] . Transcription factors are proteins that bind to specific DNA sequences and play an essential role in the regulation of gene expression. KLF5, GATA4 and GATA6 have been reported to be amplified in GC [40, 41] . It has been shown biochemically that KLF5, GATA4 and GATA6 exist in the same complex and they function co-operatively as 'lineage survival' The transcriptional regulatory network of KLF5, GATA4 and GATA6 was recently delineated using ChIP-seq where they identified a downstream gene; HNF4α co-regulated by these three transcription factors. Notably, HNF4α may be druggable by the anti-diabetic drug Metformin. This has important therapeutic implications as 30% of GC patients showed amplifications in KLF5/GATA4/GATA6 [40] . Loss of heterozygosity (LOH) or genomic deletion is another marker of CIN and frequently observed in GC. Genomic deletions can cause the loss of tumor suppressor genes, and the degree of genomic loss can be of prognostic value. For instance, LOH studies have classified GC into two subtypes: high-level LOH (LOH-H) is correlated with intestinal or mixed-typed GC, whereas low-level LOH (LOH-L) is correlated with diffuse-type GC [40, 47] . A change from LOH-L to LOH-H indicates an increase in CIN during the development of GC to a later stage. LOH in tumor suppressor genes such as APC, TP53 and NME1 is also commonly found in GC at a frequency of >30% [48] . Chromosome translocations, amplifications and rearrangement can also result in the formation of chimeric genes or fusion genes. Tao et al. identified a CD44-SLC1A2 fusion gene that is due to a chromosomal breakpoint in SLC1A2 arising via a genomic inversion. This chimeric protein may promote GC development through the alteration in metabolic pathways [49] . SLC34A2-ROS1 fusion transcripts have also been identified in GC. This genetic rearrangement is predicted to result in the constitutive activation of ROS1 which contributes to GC oncogenesis [50] . The TCGA network reported the discovery of a CLDN18-ARHGAP26 fusion gene resulting from interchromosomal translocation, and primarily occurring in genome-stable/ diffuse GC [11] . At the functional level, Yao et al. [51] showed that expression of CLDN18-ARHGAP26 in gastric epithelial cells resulted in epithelial-mesenchymal transition (EMT), which is indicative of cell transformation in cancer development. Notably, genomic instability may vary based on geographical location. The GC incidence rate in Western Europe (∼19%) is higher than that in South Africa (SA) (∼10%) despite elevated frequencies of H. pylori infection in the latter [52] . Microsatellite instable (MSI) GCs have been reported to display fewer chromosome aberrations than microsatellite stable (MSS) cancers [53] . A comparison of MSI profiles between UK and SA GC patients revealed that ∼3% of UK patients showed MSI compared with ∼24% of SA patients, whereas the analysis of DNA copy number profiles showed that UK patients displayed greater rates of chromosome gain/loss (∼27%) compared with SA patients (∼16%). Besides genomic instability, differences in the tumor microenvironment may also occur in GCs from different geographical locations. One study reported an upregulation in T-cell pathways (e.g. CTLA-4 signaling) and immune cell infiltrates in non-Asian GCs when compared with Asian GCs [54] . These different patterns of genomic instability raise the possibility of distinct biological mechanisms causing GC in patients from different geographical origins.
transcriptional changes in GC
Extensive efforts have been made to investigate transcriptional changes in GC by gene expression profiling using microarrays and, more recently, NGS techniques (RNA-sequencing). Expression signatures derived from these analyses have been used to improve diagnosis, prognosis prediction, tumor status and subgroupings of GC. For instance, Nam et al. and Vecchi et al. derived 973-and 1024-gene signatures, respectively, to distinguish tumors from normal gastric tissues. Pathways upregulated in these signatures were involved in cell migration, metastasis, cell cycle and cytoskeletal organization [55, 56] . RNA-seq profiling has also recently been used to identify the AMPKα-HNF4α-WNT5A pathway as upregulated in early-stage GC tissues [57, 58] . Hence, gene expression profiling is a promising avenue for the molecular diagnosis of early GC. Several groups have also used gene expression signatures as molecular predictors of GC prognosis. For instance, Yamada et al. [59] derived a 98-gene signature correlated with the overall survival of GC patients, and identified PDCD6 as a prognosis biomarker using endoscopic biopsies. Cho et al. [60] developed a 6-gene signature used to compute a 'risk score' to predict the relapse of GC patients after surgery, and in another study Takeno et al. [61] described a 22-gene signature to predict peritoneal relapse in patients after curative surgery, facilitating better prognosis for those with advanced GC. Finally, Lee et al. [62] identified an 8-gene signature prognostic index for stage II GC patients, allowing the stratification of patients based on this prognostic score. In these studies, prognostic signatures based on gene expression have been shown by multivariate analysis to provide survival power independent of TNM status, which is currently the gold standard for staging and prognostication for GC [59] [60] [61] [62] . This suggests that expressionbased prognostic signatures have the potential to prognosticate beyond TNM staging, but further validation is required in larger independent cohorts.
Several groups have used expression profiling to refine GC subgrouping and explored associations with clinical data including drug responses. In one study, Shah et al. [12] showed that proximal, diffuse and distal GC subtypes defined by histopathologic and anatomic criteria can be distinguished by gene expression data with >85% accuracy. In another study, Tan et al. utilized gene expression profiling to predict GC response to drug treatments. Two intrinsic genomic subtypes, G-INT and G-DIF, were established from a gene signature of 171 genes. Compared with the G-DIF subtype, G-INT subtype demonstrated greater resistance to cisplatin (Pfizer, USA) but sensitivity to 5-fluorouracil and oxaliplatin [63] . Subsequently, Lei et al. also relied on gene signatures to classify GC into three different subtypes, termed proliferative, metabolic and mesenchymal. These three subgroups showed differences in molecular and genetic features as well as responses to drug treatment. Proliferative subtypes had high levels of genomic instability, TP53 mutations and DNA hypomethylation, whereas metabolic and mesenchymal subtypes showed sensitivity to 5-fluorouracil treatment and phosphatidylinositol 3-kinase-AKT-mTOR inhibitors, respectively [64] . Interestingly, signatures related to the metabolic subtype have also recently been observed in colorectal cancer [65] . Recently, the Asian Cancer Research Group (ACRG) applied gene expression data to categorize GC into four subtypes that are associated with distinct genomic alterations, survival outcome and recurrence patterns after surgery [66] . Mesenchymal-like GCs had the worst prognosis, followed by TP53-inactive, TP53-active and finally microsatellite-instabilty tumors. Comparisons between the TCGA and ACRG classification system revealed both similarities and differences. For example, both classification systems are able to identify MSI-positive tumors, and TCGA GS, EBV+ and CIN subtypes are likely to overlap the ACRG MSS/EMT, MSS/TP53+ and MSS/TP53− subtypes, respectively. However, CDH1 and RHOA mutations, which are mutated in TCGA GS tumors, do not appear prevalent in the ACRG MSS/EMT subtypes. Such findings suggest that the TCGA and ACRG classification systems are related but distinct.
epigenetic status of GC Epigenetic mechanisms are essential for proper gene expression in tissue maintenance and development [67] . Evidence has shown that disruptions in epigenetic regulation can contribute to malignant cellular transformation of gastric cells [67] . Transcriptional inactivation by cytosine methylation at promoter CpG islands of DNA mismatch repair (MMR) or tumor suppressor genes is an important mechanism contributing to the development of several human cancers. For instance, hypermethylation of the hMLH promoter region deregulates DNA repair mechanisms resulting in the microstatellite instability (MSI) phenotype [68, 69] , which can be observed by comparing microsatellite loci in tumor and normal DNA [70] . GCs can be categorized into MSI high (MSI-H), MSI low (MSI-L) or MSS, where MSI-H GCs are more likely to have better survival than MSI-L or MSS tumors [71, 72] . Besides DNA MMR genes, tumor suppressor genes have been reported to be transcriptionally silenced due to the hypermethylation of their promoter regions leading to the development of GC [73] [74] [75] . Tumor suppressor genes, such as CDH1 and CDKN2A, have also been reported to be inactivated more frequently by epigenetic alterations than by genetic alterations [76] .
GC patients can also exhibit a CpG island methylation phenotype (CIMP) characterized by genome-wide methylation of CpG islands instead of just one gene [77, 78] . High-throughput methylation analysis by Kim et al. and Zouridis et al. reported that 35% of the GC patients are CIMP-positive [78, 79] and these patients are generally younger with worse survival outcome [79] . Kim et al. also demonstrated that CIMP-positive GC tumors are associated with oncogene mutations in genes such as CTNNB1, ERBB2, KRAS and PIK3CA [79] . DNA-demethylating drugs such as 5-azacytidine (azacitidine) and 5-aza-2 0 -deoxycytidine (decitabine) are able to restore aberrant DNA methylation and they are clinically used for patients with myelodysplastic syndromes [80] . These epigenetic drugs may be useful for the treatment of GCs and Zouridis et al. demonstrated that CIMP cell lines are sensitive to decitabine. It is noteworthy that aberrant methylation can also be induced by infectious agents such as H. pylori [81] or EBV infection [82] . Hence, understanding the epigenetic profile of GC patients may help to stratify patients for epigenetic drug treatment.
Besides DNA methylation, histone modifications also play an important part in the epigenetic modifications of a cell. In particular, trimethylation of histone H3 lysine 27 (H3K27) is a posttranslational modification that is associated with gene repression. Based on ChIP-chip studies, Zhang et al. [83] showed that gastric cancerous and matched non-cancerous tissues showed differences in the H3K27me3 status in a variety of gene classes, including oncogenes, tumor suppressor genes, cell cycle regulators and DNA repair genes. In another study carried out by Muratani et al., Nanoscale chromatin immunoprecipitation sequencing of various histone marks was carried out in GCs and matched normal tissues. They identified cryptic promoters and associated non-canonical transcripts, which could serve as novel biomarkers [84] . These studies suggest that histone modifications may serve as promising targets for epigenetic-based therapies.
conclusion GC is a heterogeneous disease likely driven by multiple genetic and epigenetic aberrations. TNM staging currently remains the gold standard for predicting patient prognosis; however, additional factors are likely important in determining the natural course and survival of GC patients. Therapeutic treatment of GC patients is also challenging, with several recent targeted therapy trials proving unsuccessful [44, 85] . With the advent of NGS, large-scale high-throughput molecular profiling studies are now providing molecular insights into the complex nature of this disease [11, 20, 41] . Studies have revealed new gene mutations, chromosomal alterations and transcriptional and epigenetic changes associated with GC ( Figure 1 ). Future work should involve clarifying, at both the functional and clinical level, which of these alterations represent bona fide GC drivers that can be harnessed as therapeutic targets and biomarkers, and validating these hypotheses in carefully designed clinical trials. Other promising areas of research include further dissection of how the environment and infectious agents (H. pylori or EBV) increase GC risk [81, 82] , and impact of the tumor microenvironment (stromal cells, immune cells and blood vessels) on GC survival and treatment responses [54, 86, 87] . Our understanding of GC is thus clearly evolving and with expanded knowledge and information; it is possible that GC patients may experience improved survivability outcomes in the near future. 
